Dosing chart / Weight & metabolic

Tirzepatide dosage

Also known as: Mounjaro, Zepbound

What is Tirzepatide?

Tirzepatide is a synthetic peptide made by Eli Lilly that activates the receptors for two gut hormones, GIP and GLP-1. Given as a once-weekly injection and first approved in the US in 2022, it is sold as Mounjaro for type 2 diabetes and as Zepbound for weight reduction and obstructive sleep apnea.

How it works

It activates both the GIP and GLP-1 receptors. GLP-1 is a natural regulator of appetite and calorie intake, and laboratory studies suggest GIP may add to that effect.

What the evidence shows

In a 72-week trial of 2,539 adults with obesity or overweight and no diabetes, average weight fell 15.0% to 20.9% across the three Zepbound maintenance strengths, versus 3.1% with placebo. In two 52-week trials totaling 469 adults with obesity and moderate to severe sleep apnea, breathing interruptions fell by about 25 to 29 events per hour versus about 5 with placebo. In a trial of 13,299 adults with type 2 diabetes and cardiovascular disease, Mounjaro was non-inferior to dulaglutide for major cardiovascular events (hazard ratio 0.92); superiority was not established. Whether it causes thyroid C-cell tumors in humans is unknown.

Reported side effects

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Indigestion
  • Injection site reactions
  • Fatigue
  • Allergic reactions
  • Belching
  • Hair loss
  • Acid reflux

Cautions

  • Boxed warning: causes thyroid C-cell tumors in rats; the risk in humans is unknown.
  • Contraindicated with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.
  • Label warnings include severe gastrointestinal reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, serious allergic reactions, and low blood sugar when combined with insulin or a sulfonylurea.
  • It may make birth control pills less effective; the label advises a non-oral or added barrier method for 4 weeks after starting and after each dose increase.
  • May cause fetal harm; the Zepbound label says to stop when pregnancy is recognized.
  • Compounded tirzepatide is not FDA-approved; the FDA had received more than 730 adverse event reports for it as of May 31, 2026.

Legal and regulatory status

FDA-approved. Mounjaro is approved to improve blood sugar control in adults and children aged 10 and older with type 2 diabetes and, since August 28, 2026, to reduce major cardiovascular events in adults with type 2 diabetes at high risk. Zepbound is approved for long-term weight reduction in adults with obesity, or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. WADA does not prohibit tirzepatide but added it to its Monitoring Program for 2026.

Common questions

What is the difference between Mounjaro and Zepbound?

Both contain tirzepatide and are made by Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight reduction and for obstructive sleep apnea in adults with obesity.

How much weight do people lose on tirzepatide?

In the main 72-week trial in the Zepbound label, adults without diabetes lost an average of 15.0% to 20.9% of body weight depending on strength, versus 3.1% with placebo. Participants also followed a reduced-calorie diet and increased physical activity.

Does tirzepatide affect birth control pills?

It can. Tirzepatide slows stomach emptying, which may reduce the effectiveness of oral hormonal contraceptives. The label advises a non-oral method or an added barrier method for 4 weeks after starting and after each dose increase.

Sources

  1. FDA: Zepbound (tirzepatide) prescribing information, revised February 2026
  2. FDA: Mounjaro (tirzepatide) prescribing information, revised April 2026
  3. Eli Lilly: FDA approves Mounjaro to reduce cardiovascular risk in adults with type 2 diabetes (August 28, 2026)
  4. FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
  5. NADA Germany: WADA publishes Prohibited List 2026

Tirzepatide reviews and Q&A

TopicRepliesLast activity

More in Weight & metabolic

Compare Tirzepatide

Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.